Page 96 - 2021_07-Haematologica-web

K. Klausz et al. 1827:381-397.
29.Staudinger M, Glorius P, Burger R, et al. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells. Blood Cancer J. 2014;4:e219.
30. Makgoba MW, Sanders ME, Ginther Luce GE, et al. A cluster of antibodies (RR1/1, LB-2 and 84H10) that inhibit LFA-1-depen- dent lymphoid and myeloid cell adhesion bind intercellular adhesion molecule-1 (ICAM-1). In: Dupont B, editor. Immunobiology of HLA. Vol II. Berlin: Springer-Verlag New York; 1989.
31. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion mole- cule (ICAM-1) distinct from LFA-1. J Immunol. 1986;137(4):1270-1274.
32. Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell. 1988; 52(6):925-933.
33. Soderlind E, Strandberg L, Jirholt P, et al. Recombining germline-derived CDR sequences for creating diverse single-frame- work antibody libraries. Nat Biotechnol. 2000;18(8):852-856.
34. Fransson J, Tornberg UC, Borrebaeck CA, Carlsson R, Frendeus B. Rapid induction of apoptosis in B-cell lymphoma by function- ally isolated human antibodies. Int J Cancer. 2006;119(2):349-358.
35. Tatsumi T, Shimazaki C, Goto H, et al. Expression of adhesion molecules on myeloma cells. Jpn J Cancer Res. 1996;87(8):837-842.
36. Van Riet I, De Waele M, Remels L, et al. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myelo- ma plasma cells. Br J Haematol. 1991; 79(3):421-427.
37. Paiva B, Corchete LA, Vidriales MB, et al. Phenotypic and genomic analysis of multi- ple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15): 1896-1906.
38. Galore-Haskel G, Baruch EN, Berg AL, et al. Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma. Oncotarget. 2017; 8(59):99580-99586.
39. Juengel E, Krueger G, Rutz J, et al. Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhe- sion. Oncotarget. 2016;7(15):20410-20424.
40. Tsai ST, Wang PJ, Liou NJ, et al. ICAM1 is a potential cancer stem cell marker of esophageal squamous cell carcinoma. PLoS One. 2015;10(11):e0142834.
41. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE. Repeat treatment of rheumatoid arthritis patients with a murine anti-inter- cellular adhesion molecule 1 monoclonal
antibody. Arthritis Rheum. 1997;40(5):849-
853.
42.Furuya K, Takeda H, Azhar S, et al.
Examination of several potential mecha- nisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti- human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke. 2001;32(11):2665-2674.
43. Wichert S, Juliusson G, Johansson A, et al. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-inter- cellular adhesion molecule-1 monoclonal antibody, in patients with smoldering mul- tiple myeloma. PLoS One. 2017; 12(2):e0171205.
44. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody iso- type-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006; 203(3):743-753.
45. Kerntke C, Nimmerjahn F, Biburger M. There Is (Scientific) Strength in numbers: a comprehensive quantitation of Fcγ receptor numbers on human and murine peripheral Blood Leukocytes. Front Immunol. 2020; 11:118.
46. Lux A, Nimmerjahn F. Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J Clin Immunol. 2013;33(Suppl 1):S4-8.
1866
haematologica | 2021; 106(7)